Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Clinical Trial of TAK-169 for the Treatment of Multiple Myeloma

Trial Profile

A Clinical Trial of TAK-169 for the Treatment of Multiple Myeloma

Phase of Trial: Phase I

Latest Information Update: 02 Dec 2018

At a glance

  • Drugs TAK 169 (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Most Recent Events

    • 02 Dec 2018 New trial record
    • 13 Nov 2018 According to a Molecular Templates media release, following the announcement of the CD38 joint development agreement in Sep 2018, Takeda and Molecular are conducting IND enabling studies for TAK-169, which is expected to enter the clinic for the treatment of multiple myeloma in 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top